-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
May 24, 2022 / eMedClub News / -- Glioblastomas (GBMs) are fast-growing gliomas, malignant grade 4 tumors that account for about 15% of all brain tumors, and are There are about 290,000 new patients worldwi.
Glioblastoma is highly aggressive, prone to recurrence, and has a high mortality and disability ra.
Currently, there is no effective long-term treatme.
A new treatment strategy is proposed in a study led by researchers at Brigham and Women's Hospital and Harvard Medical School, published in the journal Nature Communicatio.
The scientists attacked GBM-specific tumor cells by using stem cells extracted from healthy dono.
This strategy showed profound efficacy in preclinical models of GBM, with all mice surviving more than 90 days after treatme.
Many cell therapies for cancer use the patient's own stem cells or immune cel.
However, in diseases like GBM, where the disease progresses rapidly, most patients require surgery within the first week of diagnosis, leaving little time to develop treatments from their own cell typ.
To this end, the scientists developed a new method that uses allogeneic stem cells or cells from healthy individuals so that the remedy is easy to administer immediately at the time of surge.
Shah and colleagues evaluated the efficacy of several capsules that carry stem cell therapeutics in the brain and found that a biodegradable hydrogel capsule could successfully transport the therapeutics without being washed away by cerebrospinal flu.
In this study, the researchers first identified specific receptors called "death receptors" on circulating tumor cells, or cancer cells in the bloodstream, using genetic biomarkers commonly found on tumor cel.
Once identified, the researchers took stem cells from the bone marrow of healthy human donors and engineered the cells to release a protein that triggers cell death when bound to a death recept.
And the engineered stem cells can be encapsulated and stored in hydrogel capsules, which can be used for cancer cells with the same recepto.
Professor Khalid Shah, Director of the Centre for Stem Cells and Translational Immunotherapy (CSTI) and Vice-Chairman of Research at the Department of Neuroinsurance, said: "This is the first time that receptors on tumor cells have been identified before GBM therapy is initiated and biodegradable can be used post-operative.
, Gel-encapsulated, 'off-the-shelf' engineered stem cells to treat G.
In the future, once a patient is diagnosed with GBM, we can use this strategy to rapidly identify target receptors and then administer gel-encapsulated Off -the-shelf engineered stem cell therapeuti.
" They also created a safety switch in the stem cell system that allows stem cells to be tracked by PET imaging and, when activated, eradicate stem cells and further enhance cancer cell dea.
Finally, Shah's team evaluated the efficacy of therapeutic bifunctional cells (MSCBif) in post-operative animal models of primary and recurrent GBM tumo.
▲ Encapsulated stem cells (green) track and kill GBM tumor cells (red) (Image credit: SHAH LAB (CSTI)) Notably, all mice treated with gel-encapsulated stem cells after surgery were 90 days post-treatment still ali.
By comparison, mice that underwent surgery alone lived an average of 55 da.
The researchers also evaluated the safety of this clinical treatment by conducting several studies in mice using different doses of MSC thera.
They found no signs of toxicity in mice with or without tumo.
The study's results pave the way for a phase I clinical trial in GBM patients undergoing brain surgery over the next two yea.
Shah and colleagues note that this therapeutic strategy will be applicable to a wider range of solid tumors and that further investigation of its application is warrant.
Prof Shah said: "In addition to its remarkable success rate, this therapy provides a realistic basis for us to use stem cells from healthy donors to treat cancer patien.
This work provides a future opportunity to build a biobank of engineered therapeutic stem cel.
The groundwork has been la.
This biobank targets different receptors on tumor cells and immune cells in the tumor microenvironment, which we will one day be able to use to treat a variety of difficult-to-treat diseases, such as cancers like G.
" References:https://——List of recent popular events——▼May 24, Agilent Cell and Gene Therapy Webinar Series - Phase 2▼May 25, 2022 Pall Gene Therapy Series Live - Phase 1: ▼June 1, Considerations on Release Criteria for Gene Therapy--Gene Editing Off-target Detection and verify
Glioblastoma is highly aggressive, prone to recurrence, and has a high mortality and disability ra.
Currently, there is no effective long-term treatme.
A new treatment strategy is proposed in a study led by researchers at Brigham and Women's Hospital and Harvard Medical School, published in the journal Nature Communicatio.
The scientists attacked GBM-specific tumor cells by using stem cells extracted from healthy dono.
This strategy showed profound efficacy in preclinical models of GBM, with all mice surviving more than 90 days after treatme.
Many cell therapies for cancer use the patient's own stem cells or immune cel.
However, in diseases like GBM, where the disease progresses rapidly, most patients require surgery within the first week of diagnosis, leaving little time to develop treatments from their own cell typ.
To this end, the scientists developed a new method that uses allogeneic stem cells or cells from healthy individuals so that the remedy is easy to administer immediately at the time of surge.
Shah and colleagues evaluated the efficacy of several capsules that carry stem cell therapeutics in the brain and found that a biodegradable hydrogel capsule could successfully transport the therapeutics without being washed away by cerebrospinal flu.
In this study, the researchers first identified specific receptors called "death receptors" on circulating tumor cells, or cancer cells in the bloodstream, using genetic biomarkers commonly found on tumor cel.
Once identified, the researchers took stem cells from the bone marrow of healthy human donors and engineered the cells to release a protein that triggers cell death when bound to a death recept.
And the engineered stem cells can be encapsulated and stored in hydrogel capsules, which can be used for cancer cells with the same recepto.
Professor Khalid Shah, Director of the Centre for Stem Cells and Translational Immunotherapy (CSTI) and Vice-Chairman of Research at the Department of Neuroinsurance, said: "This is the first time that receptors on tumor cells have been identified before GBM therapy is initiated and biodegradable can be used post-operative.
, Gel-encapsulated, 'off-the-shelf' engineered stem cells to treat G.
In the future, once a patient is diagnosed with GBM, we can use this strategy to rapidly identify target receptors and then administer gel-encapsulated Off -the-shelf engineered stem cell therapeuti.
" They also created a safety switch in the stem cell system that allows stem cells to be tracked by PET imaging and, when activated, eradicate stem cells and further enhance cancer cell dea.
Finally, Shah's team evaluated the efficacy of therapeutic bifunctional cells (MSCBif) in post-operative animal models of primary and recurrent GBM tumo.
▲ Encapsulated stem cells (green) track and kill GBM tumor cells (red) (Image credit: SHAH LAB (CSTI)) Notably, all mice treated with gel-encapsulated stem cells after surgery were 90 days post-treatment still ali.
By comparison, mice that underwent surgery alone lived an average of 55 da.
The researchers also evaluated the safety of this clinical treatment by conducting several studies in mice using different doses of MSC thera.
They found no signs of toxicity in mice with or without tumo.
The study's results pave the way for a phase I clinical trial in GBM patients undergoing brain surgery over the next two yea.
Shah and colleagues note that this therapeutic strategy will be applicable to a wider range of solid tumors and that further investigation of its application is warrant.
Prof Shah said: "In addition to its remarkable success rate, this therapy provides a realistic basis for us to use stem cells from healthy donors to treat cancer patien.
This work provides a future opportunity to build a biobank of engineered therapeutic stem cel.
The groundwork has been la.
This biobank targets different receptors on tumor cells and immune cells in the tumor microenvironment, which we will one day be able to use to treat a variety of difficult-to-treat diseases, such as cancers like G.
" References:https://——List of recent popular events——▼May 24, Agilent Cell and Gene Therapy Webinar Series - Phase 2▼May 25, 2022 Pall Gene Therapy Series Live - Phase 1: ▼June 1, Considerations on Release Criteria for Gene Therapy--Gene Editing Off-target Detection and verify
